all semaglutide drugs Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity Weight-loss jab could be made

This stops deficiency from coming back

This process is known as the negative feedback loop

Key Growth Drivers: Increasing global obesity and diabetes burden Superior clinical efficacy in weight management Expanding indications including cardiovascular disease, MASH, CKD, and sleep apnea Growing adoption of oral GLP-1 medications Significant investments from leading pharmaceutical companies AI-powered drug discovery and innovation Expanding healthcare reimbursement and patient access As pharmaceutical leaders continue investing billions into next-generation GLP-1 therapies, this market is expected to reshape the future of cardiometabolic healthcare through 2035

Discover why board-certified supervision, weekly accountability, and a strategic Skin Investment Plan are essential to achieving results you'll actually love on your face and body

eNeuro (2019)

For the government to subsidise semaglutide or dulaglutide, you have to have diabetes, be on at least one other medication and have poor glycaemic control, says Katherine